Atrial fibrillation (AF) has a substantial genetic basis. Identification of individuals at greatest AF risk could minimize the incidence of cardioembolic stroke.
A trial fibrillation (AF) is a heritable 1 and common arrhythmia associated with substantial morbidity and economic costs. 2 Approximately 1 in 5 ischemic strokes is attributable to cardioembolic events from AF. 3 Strokes resulting from AF are associated with more disability and mortality than strokes from other causes. 4 Because many strokes caused by AF are preventable with effective anticoagulation 5 and because AF may be undetected in some individuals, there is a critical need to identify those at greatest risk for the arrhythmia.
In recent years, risk models for AF prediction have been developed that are based on clinical and demographic variables. [6] [7] [8] [9] We and others have identified common genetic variants associated with AF, [10] [11] [12] [13] [14] [15] [16] [17] and some of these variants have been associated with incident AF 18 and ischemic stroke 19 after adjustment for clinical risk factors. However, it remains unclear whether a comprehensive AF genetic risk score can facilitate the identification of individuals at greatest risk for AF or cardioembolic stroke, because such individuals might benefit from stroke prevention efforts.
We therefore sought to determine whether comprehensive AF genetic risk scores are associated with incident AF beyond clinical risk factors and might facilitate identification of individuals at greatest risk for the arrhythmia. In addition, we sought to examine whether AF genetic risk is associated with ischemic stroke and, in particular, cardioembolic stroke.
METHODS Participants
We examined the association between AF genetic risk and incident AF in 5 prospective studies. Briefly, these studies were the MDCS (Malmö Diet and Cancer Study), 20 MESA (Multi-Ethnic Study of Atherosclerosis), 21 PREVEND (Prevention of Renal and Vascular Endstage Disease), 22 PROSPER (Prospective Study of Pravastatin in the Elderly at Risk), 23 and BioVU (Vanderbilt University Deidentified DNA Biobank). 24 We also examined the association between AF genetic risk and stroke in MGH-GASROS (Massachusetts General Hospital Genes Associated With Stroke Risk and Outcomes Study), a hospital-based casereferent study of acute ischemic stroke patients (enrolled between July 2000 and 2011) and referent individuals from the Myocardial Infarction Genetics Consortium (without a history of myocardial infarction). 25, 26 All stroke cases in MGH-GASROS underwent etiologic stroke subtyping in a uniform fashion, according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria. 27 Descriptions of each study are provided in the online-only Data Supplement, including details on clinical risk factor and outcome ascertainment, genotyping, and imputation. For all analyses, samples were restricted to individuals of self-reported European ancestry. Each study was approved by its Institutional Review Board, and participants provided written informed consent.
AF Genetic Risk
To estimate genetic risk using a minimal set of single nucleotide polymorphisms (SNPs), we selected uncorrelated SNPs by pruning 28 2.2 million HapMap variants included in a prior independent meta-analysis of genome-wide association studies for AF from the AFGen consortium (6707 individuals with and 53 436 without AF). 15 We considered all SNPs that had allele frequencies ≥5% and were nominally associated with AF (P<1×10 −3 ). We then selected the most significantly associated SNP within a given 250-kilobase locus that was not in linkage disequilibrium with another more significantly associated SNP at that locus (r 2 <0.1). In total, 719 uncorrelated SNPs were selected for construction of genetic risk scores (Table I in  the online-only Data Supplement) .
For each individual, we calculated AF genetic risk scores by summing the dosage of each AF risk allele (ranging from 0-2) weighted by the natural logarithm of the relative risk for each SNP. Weights were determined in our earlier, independent meta-analysis. 15 Thus, a genetic risk score for an individual is a single linear predictor variable. Because the optimum number of risk alleles that should be used for genetic risk scores has not been fixed, we constructed 7 different scores for each
Clinical Perspective
What Is New?
• Studies have identified several genetic loci associated with atrial fibrillation (AF), yet it is unclear whether genetic profiling can identify individuals at greatest risk for AF or cardioembolic stroke.
• Using genome-wide data from an independent largescale analysis, we tested comprehensive AF genetic risk scores for association with new-onset AF in 5 prospective studies and with stroke in a separate stroke case-referent sample.
• Genetic risk scores were associated with AF beyond established clinical risk factors but improved prediction minimally.
• AF genetic risk was strongly associated with cardioembolic stroke, suggesting that elevated AF genetic risk might serve as a surrogate for thromboembolism from AF.
What Are the Clinical Implications?
• individual on the basis of the strength of association between each SNP and AF in the earlier analysis. 15 We selected the 7 different significance thresholds a priori: P<1×10 −3 , <1×10 −4 , <1×10 −5 , <1×10 −6 , <1×10 −7 , <5×10 −8 , and <1×10 −8 . Liberal inclusion of SNPs was motivated by observations that uncorrelated SNPs demonstrating less significant associations with a trait may still explain a substantial proportion of the heritability of the trait.
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Statistical Analysis
Within each prospective study, we used proportional hazards regression to examine associations between the different AF genetic risk scores and incident AF over a 5-year time horizon. For all incident AF analyses, person-time in each cohort began at DNA collection or baseline enrollment. Individuals were treated as censored at the time of death or loss to followup. Models were adjusted for variables included in a previously validated composite risk score for 5-year AF risk prediction (CHARGE [Cohorts for Heart and Aging Research in Genomic Epidemiology]-AF risk score). 9 The composite CHARGE-AF risk score included age, height, weight, systolic and diastolic blood pressures, smoking status, antihypertensive medication use, diabetes status, heart failure status, myocardial infarction status, electrocardiographic evidence of left ventricular hypertrophy, and PR interval. Electrocardiographic variables that were not available were omitted from the scores on a study-by-study basis (left ventricular hypertrophy was unavailable in MDCS, MESA, PREVEND, and PROSPER; PR interval was unavailable in MDCS, PREVEND, PROSPER, and BioVU). Race was not included in the models because we restricted our sample to individuals of European ancestry. Proportional hazards assumptions were verified with multiplicative interaction terms between covariates and the natural logarithm of follow-up time.
For each model, we calculated goodness-of-fit statistics using the Akaike Information Criterion, a penalized likelihood metric in which lower values indicate better fit. 33 We also assessed discrimination using the C statistic for time-to-event data. 34 Calibration of the prediction models was assessed with the Hosmer-Lemeshow statistic modified for survival analysis. 35 In exploratory analyses, we combined model parameters from each study by use of an inverse variance random-effects meta-analysis approach and calculated heterogeneity using the I 2 statistic. 36 We used a random-effects approach owing to inherent differences in study design (see Methods in the onlineonly Data Supplement). We multiplied the summary score β coefficient by the difference between the 12.5th and 87.5th percentiles of AF genetic risk scores from a common reference population (Table II in the online-only Data Supplement).
The resulting values estimate the relative risk comparing individuals in the highest and lowest quartiles across each study and score in a standard fashion. The common reference population used was a pooled sample of 12 801 individuals from the Framingham Heart Study (n=2551), 37 the Atherosclerosis Risk in Communities Study (n=7278), 38 and the Cardiovascular Health Study (n=2972) 39 with genome-wide genotyping data. 15 We then examined whether AF genetic risk was associated with AF, ischemic stroke, and cardioembolic stroke in MGH-GASROS using multivariable logistic regression. Because several of the identified pruned AF SNPs were not available in the MGH-GASROS sample, we used proxy SNPs on the basis of linkage disequilibrium if available (Table I in the online-only Data Supplement). The number of SNPs in some genetic risk scores differed slightly on the basis of inability to identify proxies. Models were adjusted for age and sex only because extended clinical information was not available in the referent participants. We examined associations between AF genetic risk and ischemic stroke, as well as with the TOAST cardioembolic stroke classification (a subset of ischemic stroke). We used the same referent sample set for analyses of ischemic and cardioembolic stroke. Because AF may occur as a subclinical condition, we examined in exploratory analyses whether AF genetic risk scores were associated with stroke in individuals without known AF. Because AF was ascertained only in stroke cases, we assumed that AF was not present among referents for analyses of AF and in analyses in which we excluded individuals with known AF (an assumption that would be expected to bias the results toward a null association between genetic risk and AF as a result of the potential for misclassified individuals who have AF among the referent sample).
None of the studies in our analysis of incident AF were used in any aspect of the derivation of genetic risk or the CHARGE-AF scores. The a priori significance threshold for all analyses was P<0.05 using 2-sided tests. Meta-analyses were conducted with the rmeta 40 package in R. 41 Other software used for analyses is described in the online-only Data Supplement.
RESULTS
AF Genetic Risk Scores and Incident AF
Among 18 919 individuals across all studies in our analyses of incident AF, the mean age ranged from 58 to 75 years, and the proportion of women ranged from 47% to 52%. During the 5-year follow-up window, 1032 individuals (5.5%) developed incident AF (Table 1) . AF genetic risk scores were associated with incident AF after accounting for clinical risk factors (Figure I and Table III in the online-only Data Supplement). Heterogeneity of effect estimates was modest between studies. Generally, the models with the best fit included scores with 25 to 129 SNPs, as indicated by the Akaike Information Criterion (Table III in ) increased hazard for AF (Figure 1 ). C statistics for the clinical risk factor model without AF genetic risk scores ranged from 0.615 to 0.802 across cohorts (Table III in 
AF Genetic Risk Scores and Ischemic Stroke
We examined the association between AF genetic risk scores and stroke among 509 independent individuals with stroke from MGH-GASROS and 3028 referents (Table 2). Among the stroke cases, 202 (40%) were classified as having had a cardioembolic stroke by TOAST criteria. In total, 87 individuals (17%) with ischemic stroke had documented AF.
In MGH-GASROS, modest associations between AF genetic risk scores and AF, ischemic stroke (all subtypes), and the subset of cases with cardioembolic stroke were observed with the use of continuous genetic risk scores (Table IV in the online-only Data Supplement). The most significantly associated score with AF, as judged by the score with the smallest P value, occurred with a score constructed from 127 SNPs, corresponding to SNPs with P<1×10 −4 for associations with AF in the prior independent AFGen analysis. 15 Individuals in the highest quartile of the 127-SNP genetic risk score had a 3.13-fold (95% CI, 1.47-7.21; P=0.005) increased odds of AF relative to those in the lowest quartile.
In the analysis of ischemic stroke cases and referent individuals, AF genetic risk scores were also modestly associated with both ischemic stroke (all subtypes) and cardioembolic stroke (Table III in History of smoking, n (%) 2513 (31) 1401 (55) 671 (41) 1388 (27) 619 (45) Antihypertensive medication, n (%) 1799 (22) 840 (33) 362 (22) 3854 (74) 1339 (96) History of diabetes mellitus, n (%) 542 (7) 151 (6) 98 (6) 540 (10) 359 (26) History of heart failure, n (%) 39 (0. Single nucleotide polymorphisms (SNPs) included in scores were derived with the use of different thresholds of association between each SNP and AF in an earlier, independent study. 15 had cardioembolic strokes) were omitted, the associations between AF genetic risk and both ischemic and cardioembolic stroke remained but were slightly attenuated ( factors was small regardless of the number of SNPs included in the genetic risk score. In an independent sample, individuals in the highest quartile of a score made up of 127 AF-associated genetic markers had roughly 2-fold higher odds of cardioembolic stroke compared with those in the lowest quartile after adjustment for age and sex. Associations between AF genetic risk scores and cardioembolic stroke persisted after the exclusion of individuals with known AF. Our findings support and extend prior observations that AF genetic risk is associated with both AF and stroke. We previously observed an association between familial AF and incident AF in the Framingham Heart Study, beyond associations for clinical risk factors. 1 Subsequently, we observed an ≈4-to 5-fold gradient in risk between those in the highest versus lowest tails of a 12-SNP AF genetic risk score (based on 9 loci) in case-referent and cohort studies. 16 The Women's Genome Health Study reported an association between an AF genetic risk score based on 12 SNPs and occurrence of incident AF, 18 although some of the AFassociated SNPs used in the analysis were identified in a previous discovery study using subjects from the same sample. Earlier work also described associations between ischemic (and, in particular, cardioembolic) stroke and the top AF-associated variants at chromosome regions 4q25 and 16q22. 13, 26, [42] [43] [44] Recently, we and others reported a 2-fold increased hazard of AF and a 1.23-fold increased hazard of ischemic stroke for individuals in the highest versus lowest quintiles of scores based on a 12-SNP genetic risk model during an average follow-up of 14 years in the MDCS, subjects of which were included in the present analysis of incident AF. 19 Thus, by using well-characterized independent study samples, our present findings extend prior reports that AF genetic risk is associated with incident AF and ischemic stroke.
Our observations have 3 major implications. First, our finding that AF genetic risk is associated with incident AF beyond the effects observed for accepted clinical risk factors highlights the ability of common genetic variation to capture complementary information. Indeed, the 28% to 67% increased risk of AF among individuals in the highest versus the lowest quartile of genetic risk is comparable to the magnitude of risk conferred by traditional clinical risk factors for AF. 9 Nevertheless, even with the inclusion of a large number of genetic variants and assessment of associations with incident AF in large cohorts, the magnitudes of risk associated with genetic risk improved discrimination minimally beyond clinical factors. Such findings underscore the challenges of improving clinical prediction models even when highly associated predictors are included. 45 Second, our observations, coupled with prior findings that AF genetic risk may be preferentially associated with cardioembolic stroke, 13, 42, 43 raise the possibility that AF genetic risk may serve as a signature for strokes caused by thromboembolism due to AF. Our observation that AF genetic risk was associated with an increased risk of cardioembolic stroke even after the exclusion of individuals with known AF is consistent with the hypothesis that AF genetic risk may be a clinically relevant marker for subclinical or previously undiagnosed AF. Although AF genetic risk has a limited impact beyond knowledge of clinical risk factors on AF prediction over a 5-year time horizon, it is possible that such genetic profiling may provide insights into stroke mechanisms and therefore screening and treatment options for secondary prevention. Future analyses are warranted to determine whether AF genetic risk discriminates effectively between different stroke subtypes, to assess whether AF genetic risk can identify cryptogenic stroke patients at elevated risk for recurrent stroke caused by AF, and to determine whether estimating AF risk can enhance secondary stroke prevention efforts.
Third, our observation that genetic risk scores constructed from liberally selected SNPs were nevertheless associated with AF and AF-related stroke emphasizes the polygenic nature of AF. Therefore, true AF susceptibility variants are likely to exist although they may not meet the stringent genome-wide significance criteria currently used. Future genetic discovery efforts in larger samples with better power are warranted to identify additional AF susceptibility signals. Indeed, since publication of the most recent AFGen meta-analysis, 15 additional bona fide subthreshold AF signals have been identified, and some appear to be associated with stroke. 17 It remains to be determined whether future assessment of AF genetic risk based on associations derived from larger samples will enhance the specificity of prediction models.
Our study should be interpreted in the context of the study design. First, all participants were of Eu- 46 Similarly, in analyses of ischemic stroke, clinical covariates beyond age and sex were unavailable, so we could not evaluate whether the genetic risk score adds appreciably to prediction afforded by the CHA 2 DS 2 -VASc score 47 or individual stroke risk factors. Future studies are warranted to determine whether genetic risk adds information to other clinical and biomarker factors related to AF and stroke. Fourth, our genetic risk models comprised common SNPs genotyped in the HapMap reference populations, 48 many of which are likely tag-SNPs and serve as proxies for true causal variation. Through the use of larger sample sizes and newer techniques to comprehensively assess genomic variation such as whole-genome sequencing, we anticipate better power to identify causal variants underlying AF in the future. Inclusion of causal variants in genetic risk scores may improve the specificity of the models. Fifth, the genetic predictors of prevalent stroke may not be identical to those of incident stroke because of potential survival biases. Therefore, the clinical utility of AF genetic risk factors for identifying individuals at risk for incident stroke merits future study.
CONCLUSIONS
We observed that comprehensive AF genetic risk scores were associated with incident AF, exceeding associations of clinical risk factors, in individuals of European ancestry. We further observed that AF genetic risk is associated with both ischemic and cardioembolic stroke after adjustment for age and sex, even among individuals with cardioembolic stroke without established AF. Our findings underscore the polygenic nature of AF and the independent value of genetic information beyond clinical risk factors for the identification of individuals at risk for AF. However, although genetic risk scores are highly associated with AF, genetic information currently affords small improvements in discrimination of AF risk and therefore does not yet need to be incorporated into routine clinical decision making. Future clinical trials are necessary to rigorously assess whether AF genetic risk is an effective clinical marker of cardioembolic stroke cause and can identify individuals with subclinical AF.
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